Next-generation wearable ATTFields platform delivering adaptive, noninvasive tumor-treating fields to target multiple metastatic tumors across the torso. Based on FDA-approved TTFields therapy, offers smarter targeting, broader coverage and higher therapeutic dosage to treat Stage IV metastatic cancer patients while preserving comfort and quality of life.